Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma

Research output: Contribution to journalArticle

Dunrui Wang, Navneet Narula, Stephanie Azzopardi, Roger S. Smith, Abu Nasar, Nasser K. Altorki, Vivek Mittal, Romel Somwar, Brendon M. Stiles, Yi Chieh Nancy Du

The receptor for hyaluronic acid-mediated motility (RHAMM) is upregulated in various cancers, but its role in primary and metastatic non-small cell lung carcinoma (NSCLC) remains to be determined. Here, we investigate the clinical relevance of RHAMM expression in NSCLC. RHAMM protein expression correlates with histological differentiation stages and extent of the primary tumor (T stages) in 156 patients with primary NSCLC. Importantly, while focal RHAMM staining pattern is present in 57% of primary NSCLC, intense RHAMM protein expression is present in 96% of metastatic NSCLC cases. In a publicly available database, The Cancer Genome Atlas (TCGA), RHAMM mRNA expression is 12- and 10-fold higher in lung adenocarcinoma and squamous lung carcinoma than in matched normal lung tissues, respectively. RHAMM mRNA expression correlates with stages of differentiation and inferior survival in more than 400 cases of lung adenocarcinoma in the Director's Challenge cohort. Of 4 RHAMM splice variants, RHAMMv3 (also known as RHAMMB) is the dominant variant in NSCLC. Moreover, shRNA-mediated knockdown of RHAMM reduced the migratory ability of two lung adenocarcinoma cell lines, H1975 and H3255. Taken together, RHAMM, most likely RHAMMv3 (RHAMMB), can serve as a prognostic factor for lung adenocarcinomas and a potential therapeutic target in NSCLC to inhibit tumor migration.

Original languageEnglish (US)
Pages (from-to)39957-39969
Number of pages13
JournalOncotarget
Volume7
Issue number26
StatePublished - 2016

PMID: 27220886

Cite this

Standard

Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma. / Wang, Dunrui; Narula, Navneet; Azzopardi, Stephanie; Smith, Roger S.; Nasar, Abu; Altorki, Nasser K.; Mittal, Vivek; Somwar, Romel; Stiles, Brendon M.; Nancy Du, Yi Chieh.

In: Oncotarget, Vol. 7, No. 26, 2016, p. 39957-39969.

Research output: Contribution to journalArticle

Harvard

Wang, D, Narula, N, Azzopardi, S, Smith, RS, Nasar, A, Altorki, NK, Mittal, V, Somwar, R, Stiles, BM & Nancy Du, YC 2016, 'Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma' Oncotarget, vol. 7, no. 26, pp. 39957-39969.

APA

Wang, D., Narula, N., Azzopardi, S., Smith, R. S., Nasar, A., Altorki, N. K., ... Nancy Du, Y. C. (2016). Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma. Oncotarget, 7(26), 39957-39969.

Vancouver

Wang D, Narula N, Azzopardi S, Smith RS, Nasar A, Altorki NK et al. Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma. Oncotarget. 2016;7(26):39957-39969.

Author

Wang, Dunrui ; Narula, Navneet ; Azzopardi, Stephanie ; Smith, Roger S. ; Nasar, Abu ; Altorki, Nasser K. ; Mittal, Vivek ; Somwar, Romel ; Stiles, Brendon M. ; Nancy Du, Yi Chieh. / Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma. In: Oncotarget. 2016 ; Vol. 7, No. 26. pp. 39957-39969.

BibTeX

@article{cb49292ed1fe4f60853e69a5610eea18,
title = "Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma",
abstract = "The receptor for hyaluronic acid-mediated motility (RHAMM) is upregulated in various cancers, but its role in primary and metastatic non-small cell lung carcinoma (NSCLC) remains to be determined. Here, we investigate the clinical relevance of RHAMM expression in NSCLC. RHAMM protein expression correlates with histological differentiation stages and extent of the primary tumor (T stages) in 156 patients with primary NSCLC. Importantly, while focal RHAMM staining pattern is present in 57{\%} of primary NSCLC, intense RHAMM protein expression is present in 96{\%} of metastatic NSCLC cases. In a publicly available database, The Cancer Genome Atlas (TCGA), RHAMM mRNA expression is 12- and 10-fold higher in lung adenocarcinoma and squamous lung carcinoma than in matched normal lung tissues, respectively. RHAMM mRNA expression correlates with stages of differentiation and inferior survival in more than 400 cases of lung adenocarcinoma in the Director's Challenge cohort. Of 4 RHAMM splice variants, RHAMMv3 (also known as RHAMMB) is the dominant variant in NSCLC. Moreover, shRNA-mediated knockdown of RHAMM reduced the migratory ability of two lung adenocarcinoma cell lines, H1975 and H3255. Taken together, RHAMM, most likely RHAMMv3 (RHAMMB), can serve as a prognostic factor for lung adenocarcinomas and a potential therapeutic target in NSCLC to inhibit tumor migration.",
keywords = "Lung cancer, Metastasis, Prognosis, Receptor for hyaluronic acid-mediated motility",
author = "Dunrui Wang and Navneet Narula and Stephanie Azzopardi and Smith, {Roger S.} and Abu Nasar and Altorki, {Nasser K.} and Vivek Mittal and Romel Somwar and Stiles, {Brendon M.} and {Nancy Du}, {Yi Chieh}",
year = "2016",
language = "English (US)",
volume = "7",
pages = "39957--39969",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "26",

}

RIS

TY - JOUR

T1 - Expression of the receptor for hyaluronic acid mediated motility (RHAMM) is associated with poor prognosis and metastasis in non-small cell lung carcinoma

AU - Wang, Dunrui

AU - Narula, Navneet

AU - Azzopardi, Stephanie

AU - Smith, Roger S.

AU - Nasar, Abu

AU - Altorki, Nasser K.

AU - Mittal, Vivek

AU - Somwar, Romel

AU - Stiles, Brendon M.

AU - Nancy Du, Yi Chieh

PY - 2016

Y1 - 2016

N2 - The receptor for hyaluronic acid-mediated motility (RHAMM) is upregulated in various cancers, but its role in primary and metastatic non-small cell lung carcinoma (NSCLC) remains to be determined. Here, we investigate the clinical relevance of RHAMM expression in NSCLC. RHAMM protein expression correlates with histological differentiation stages and extent of the primary tumor (T stages) in 156 patients with primary NSCLC. Importantly, while focal RHAMM staining pattern is present in 57% of primary NSCLC, intense RHAMM protein expression is present in 96% of metastatic NSCLC cases. In a publicly available database, The Cancer Genome Atlas (TCGA), RHAMM mRNA expression is 12- and 10-fold higher in lung adenocarcinoma and squamous lung carcinoma than in matched normal lung tissues, respectively. RHAMM mRNA expression correlates with stages of differentiation and inferior survival in more than 400 cases of lung adenocarcinoma in the Director's Challenge cohort. Of 4 RHAMM splice variants, RHAMMv3 (also known as RHAMMB) is the dominant variant in NSCLC. Moreover, shRNA-mediated knockdown of RHAMM reduced the migratory ability of two lung adenocarcinoma cell lines, H1975 and H3255. Taken together, RHAMM, most likely RHAMMv3 (RHAMMB), can serve as a prognostic factor for lung adenocarcinomas and a potential therapeutic target in NSCLC to inhibit tumor migration.

AB - The receptor for hyaluronic acid-mediated motility (RHAMM) is upregulated in various cancers, but its role in primary and metastatic non-small cell lung carcinoma (NSCLC) remains to be determined. Here, we investigate the clinical relevance of RHAMM expression in NSCLC. RHAMM protein expression correlates with histological differentiation stages and extent of the primary tumor (T stages) in 156 patients with primary NSCLC. Importantly, while focal RHAMM staining pattern is present in 57% of primary NSCLC, intense RHAMM protein expression is present in 96% of metastatic NSCLC cases. In a publicly available database, The Cancer Genome Atlas (TCGA), RHAMM mRNA expression is 12- and 10-fold higher in lung adenocarcinoma and squamous lung carcinoma than in matched normal lung tissues, respectively. RHAMM mRNA expression correlates with stages of differentiation and inferior survival in more than 400 cases of lung adenocarcinoma in the Director's Challenge cohort. Of 4 RHAMM splice variants, RHAMMv3 (also known as RHAMMB) is the dominant variant in NSCLC. Moreover, shRNA-mediated knockdown of RHAMM reduced the migratory ability of two lung adenocarcinoma cell lines, H1975 and H3255. Taken together, RHAMM, most likely RHAMMv3 (RHAMMB), can serve as a prognostic factor for lung adenocarcinomas and a potential therapeutic target in NSCLC to inhibit tumor migration.

KW - Lung cancer

KW - Metastasis

KW - Prognosis

KW - Receptor for hyaluronic acid-mediated motility

UR - http://www.scopus.com/inward/record.url?scp=84982915244&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982915244&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 39957

EP - 39969

JO - Oncotarget

T2 - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 26

ER -

ID: 26850775